Navigation Links
NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Date:12/14/2007

SOPHIA ANTIPOLIS, France, Dec. 14 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced it has successfully completed the enrollment of 1020 patients in the 302 pivotal phase 3 study for naproxcinod, in-line with projections. Naproxcinod is the Company's lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class. The 302 study is designed to assess naproxcinod's efficacy for treating the signs and symptoms of osteoarthritis and provide additional blood pressure data, which is a key factor for differentiating naproxcinod from existing anti-inflammatory treatments. Efficacy results from this study are anticipated in the third quarter of 2008.

The 302 study represents the largest of the three pivotal phase 3 trials for naproxcinod (the 301, 302 and 303 studies). The 301 study is complete and results were recently presented at the 71st annual meeting of the American College of Rheumatology (ACR), which showed that naproxcinod met all three co-primary efficacy endpoints and demonstrated a similar effect on systolic blood pressure to placebo and a reduction compared to naproxen, a commonly used anti-inflammatory agent. The third and final study (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is well underway, following its initiation in June 2007. Current timelines are that the 303 study should complete enrollment in the second quarter of 2008, with results expected by the end of 2008. NicOx now anticipates the filing of a New Drug Application (NDA) for naproxcinod with the US Food and Drug Administration (FDA) in mid-2009.

"The 302 study is the largest and longest duration trial in our program for naproxcinod and our clinical team has proved its effectiveness in successfully recruiting the targeted number of patients in-line with projected timelines," said Pascal Pfister, Chief Scientific Officer of NicOx. "The 302 study will p
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... YORK , Sept. 19, 2014 Harwood ... against the board of directors of PDL BioPharma, Inc. ... concerning whether the board has breached its fiduciary duties ... On September 16, 2014, the Company disclosed: "On ... independent registered accounting firm, Ernst & Young LLP ("EY"), ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 /PRNewswire-USNewswire/ ... often used to inflate sales of brand drugs ... Part D,  according to a new report ... Services Office of the Inspector General (OIG). Federal anti-kickback ... sales of goods that are subsidized by the ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic ... Inc. announced today that the first patient has ... a small molecule Stem Cell Modulator (SCM) designed to increase ... of key pathways that guide cell fate. The study, ...
... W.Va., May 27 The Blanchette Rockefeller Neurosciences ... NYSE: IMA ) of Waltham, Massachusetts, a ... announced today that they will work together to ... Alzheimer,s disease first discovered by scientists at BRNI. ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 2Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 3Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 4
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the leading ... GreenGeeks are the best Reseller hosting suppliers in 2014. ... supplier. Actually, these companies have outperformed their competitors on ... can get the best web hosting at affordable rates,” ... the manager, reseller hosting is a very popular way ...
(Date:9/21/2014)... Originally approved by the Food ... (fluticasone propionate) is a synthetic ICS therapy with ... maintenance treatment of asthma prophylactically in children and ... Diskus and HFA, which received the FDA approval ... fluticasone propionate, can bind to glucocorticoid receptors with ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
Breaking Medicine News(10 mins):Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... University of New York at the Buffalo School of Dental ... fibrinogen, a protein useful in blood clotting may increase the ... gums, those with gum disease carry certain gene variations linked ... , 79 people with gum ...
... In a landmark breakthrough, scientists have created mice with unusually ... also opening a possibility of helping people forget their distressing ... the molecular processes that govern memory and learning in the ... Technology in Zurich. , ...
... expands into Optical Coherence Tomography. This breakthrough has made many ... This has been developed by Dr. Brett Bouma an assistant ... tomography to gauge stent status.// , ... ultrasound and will allow cardiologists to view the status of ...
... on more than 1600 women reveals that parathyroid hormone (parathormone) increases ... them. The same hormone is also useful in regulating calcium levels ... new aspect of the hormone guarding against fractures has opened up ... brittle bone disease as it is also known as.// , ...
... May 24th issue of Nature reveals that the Obesity Hormone ... in more complex way than previously believed. This break through ... Obesity and many nutrition related disorders like anorexia nervosa. Dr. ... led the study. , ...
... actually repair itself by growing new cells after a heart ... York and Italy. Dr. Piero Anversa and colleagues of the ... muscle cells called myocytes continued to divide after a heart ... team examined the hearts of 13 people who died within ...
Cached Medicine News:
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Medicine Products: